Role of EZH2 in oral squamous cell carcinoma carcinogenesis

Gene

Volumn 537, Issue 2, 2014, Pages 197-202

  Zhao, Lingbo ^a   Yu, Yang ^b   Wu, Jie ^b   Bai, Jing ^b   Zhao, Yuzhen ^b   Li, Chunming ^a   Sun, Wenjing ^b   Wang, Xiumei ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

EZH2; Oncogene; Oral squamous cell carcinoma

Indexed keywords

POLYCOMB GROUP PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2;

APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KERATINOCYTE; METASTASIS INHIBITION; MOUTH SQUAMOUS CELL CARCINOMA; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR EZH2 GENE; WOUND HEALING;

A SPECIFIC HISTONE 3 LYSINE 27; DMEM; DULBECCO'S MODIFIED EAGLE'S MEDIUM; EGFR; ENHANCER OF ZESTE HOMOLOG 2; EPITHELIAL GROWTH FACTOR RECEPTOR; EZH2; FBS; FETAL BOVINE SERUM; GAPDH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; H3K27; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HNSCC; ONCOGENE; ORAL SQUAMOUS CELL CARCINOMA; OSCC; POLYVINYLIDENE DIFLUORIDE; PVDF; QRT-PCR; QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOUTH NEOPLASMS; ONCOGENES; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84893664613     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.01.006     Document Type: Article

References (28)

1. Alford S.H., Toy K., Merajver S.D., Kleer C.G. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res. Treat. 2011, 132:429-437.
2. Borbone E., Troncone G., Ferraro A., Jasencakova Z., Stojic L., Esposito F., Hornig N., Fusco A., Orlando V. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J. Clin. Endocrinol. Metab. 2011, 96:1029-1038.
3. Cao W., Younis R.H., Li J., Chen H., Xia R., Mao L., Chen W., Ren H. EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev. Res. 2011, 4:1816-1824.
4. Chang C.-J., et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011, 19:86-100.
5. Chen J.H., Yeh K.T., Yang Y.M., Chang J.G., Lee H.E., Hung S.Y. High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan. Med. Oncol. 2013, 30:513.
6. Choi S., Myers J.N. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 2008, 87:14-32.
7. Gonzalez M.E., et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009, 28:843-853.
8. He L.-J., et al. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac. J. Cancer Prev. 2012, 13:3173-3178.
9. Hock H. A complex polycomb issue: the two faces of EZH2 in cancer. Genes Dev. 2012, 26:751-755.
10. Hu S., et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 2010, 10:788-795.
11. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
12. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
13. Karanikolas B.D.W., Figueiredo M.L., Wu L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol. Cancer Res. 2009, 7:1456-1465.
14. Kidani K., et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 2009, 45:39-46.
15. Kim W., et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 2013, 9:643-650.
16. Li H., Zhang R. Role of EZH2 in epithelial ovarian cancer: from biological insights to therapeutic target. Front. Oncol. 2013, 3:47.
17. Mishra R., Das B.R. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. Arch. Oral Biol. 2009, 54:917-923.
18. Murugan A.K., Munirajan A.K., Tsuchida N. Ras oncogenes in oral cancer: the past 20years. Oral Oncol. 2012, 48:383-392.
19. Nakagawa S., et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann. Surg. Oncol. 2013, 3:667-675. 10.1245/s10434-013-3135-y.
20. Pai R.B. Overexpression of c-Myc oncoprotein in oral squamous cell carcinoma in the south Indian population. Cancer Med. Sci. 2009, 3:128. 10.3332/ecancer.2008.128.
21. Preuss S.F., et al. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br. J. Cancer 2008, 98:627-632.
22. Raman J.D. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 2005, 11:8570-8576.
23. Sarkis S.A., Abdullah B.H., Abdul Majeed B.A., Talabani N.G. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol. 2010, 2:13.
24. Sasaki M., Ikeda H., Itatsu K., Yamaguchi J., Sawada S., Minato H., Ohta T., Nakanuma Y. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Investig. 2008, 88:873-882.
25. Scully C. Oral cancer aetiopathogenesis; past, present and future aspects. Medicina Oral Patología Oral y Cirugia Bucal 2011, e306-e311.
26. Tang D.G., Shin Y.J., Kim J.-H. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS ONE 2012, 7:e30393.
27. Wagener N., et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524.
28. Wu Z., Lee S.T., Qiao Y., Li Z., Lee P.L., Lee Y.J., Jiang X., Tan J., Aau M., Lim C.Z.H., Yu Q. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011, 18:1771-1779.